PRELUDE CAPITAL MANAGEMENT, LLC - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBERWS and the CUSIP is G46843119. A total of 33 filers reported holding IBERE PHARMACEUTICALS in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q3 2022$1,0000.0%13,5010.0%0.00%
Q2 2022$1,000
-66.7%
13,5010.0%0.00%
Q1 2022$3,000
-70.0%
13,501
-27.0%
0.00%
Q4 2021$10,000
-9.1%
18,501
+2.2%
0.00%
Q3 2021$11,000
-15.4%
18,101
+2.3%
0.00%
Q2 2021$13,00017,7010.00%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q4 2021
NameSharesValueWeighting ↓
Knott David M Jr 18,000$207,0000.09%
Hartree Partners, LP 642,500$51,400,0000.04%
Radcliffe Capital Management, L.P. 150,000$1,487,0000.04%
TEGEAN CAPITAL MANAGEMENT, LLC 45,710$2,0020.01%
MARSHALL WACE, LLP 224,997$2,231,0000.01%
Ayrton Capital LLC 28,393$2,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 13,499$134,0000.00%
EHP Funds Inc. 109,569$11,0000.00%
COWEN AND COMPANY, LLC 250,974$21,0000.00%
Alpine Global Management, LLC 61,625$5,0000.00%
View complete list of IBERE PHARMACEUTICALS shareholders